

Network Systems  
Science & Advanced  
Computing  
Biocomplexity Institute  
& Initiative  
University of Virginia

# Estimation of COVID-19 Impact in Virginia

October 26<sup>th</sup>, 2022

(data current to October 22<sup>nd</sup> – October 25<sup>th</sup>)

Biocomplexity Institute Technical report: TR BI-2022-1775



---

**BIOCOMPLEXITY** INSTITUTE

[biocomplexity.virginia.edu](https://biocomplexity.virginia.edu)

# About Us

- Biocomplexity Institute at the University of Virginia
  - Using big data and simulations to understand massively interactive systems and solve societal problems
- Over 20 years of crafting and analyzing infectious disease models
  - Pandemic response for Influenza, Ebola, Zika, and others



## Points of Contact

Bryan Lewis  
[brylew@virginia.edu](mailto:brylew@virginia.edu)

Srini Venkatramanan  
[srini@virginia.edu](mailto:srini@virginia.edu)

Madhav Marathe  
[marathe@virginia.edu](mailto:marathe@virginia.edu)

Chris Barrett  
[ChrisBarrett@virginia.edu](mailto:ChrisBarrett@virginia.edu)

## Model Development, Outbreak Analytics, and Delivery Team

Przemyslaw Porebski, Joseph Outten, Brian Klahn, Alex Telionis,  
Srinivasan Venkatramanan, Bryan Lewis,

Aniruddha Adiga, Hannah Baek, Chris Barrett, Jiangzhuo Chen, Patrick Corbett,  
Stephen Eubank, Galen Harrison, Ben Hurt, Dustin Machi, Achla Marathe,  
Madhav Marathe, Mark Orr, Akhil Peddireddy, Erin Raymond, James Schlitt, Anil Vullikanti,  
Lijing Wang, James Walke, Andrew Warren, Amanda Wilson, Dawen Xie



# Overview

- **Goal:** Understand impact of COVID-19 mitigations in Virginia
- **Approach:**
  - Calibrate explanatory mechanistic model to observed cases
  - Project based on scenarios for next 4 months
  - Consider a range of possible mitigation effects in "what-if" scenarios
- **Outcomes:**
  - Ill, Confirmed, Hospitalized, ICU, Ventilated, Death
  - Geographic spread over time, case counts, healthcare burdens

# Key Takeaways

Projecting future cases precisely is impossible and unnecessary.

Even without perfect projections, we can confidently draw conclusions:


- **Case rates have continued to decline though hospitalizations have shown some recent growth**
- VA weekly case rate is slightly down at 81 per 100K from 84 per 100K
  - US weekly case rate is flat remaining at 74 per 100K from 74 per 100K
  - VA hospital occupancy (rolling 7 day mean of 455 slightly down from 482 a week ago) down but experiencing recent activity
- Sub-variant prevalence has started to grow rapidly, BA.5 subvariants seem to be accelerating
- Projections from last week remain largely on target with limited impact of Fall Winter scenario, however hospitalization trajectories

The situation continues to change. Models continue to be updated regularly.

# Situation Assessment

---


# Case Rates (per 100k) and Test Positivity



# District Trajectories

**Goal:** Define epochs of a Health District's COVID-19 incidence to characterize the current trajectory

**Method:** Find recent peak and use hockey stick fit to find inflection point afterwards, then use this period's slope to define the trajectory





Trajectory	Description	Weekly Case Rate Slope (per 100k)	Weekly Hosp Rate Slope (per 100k)
<b>Declining</b>	Sustained decreases following a recent peak	slope < -0.88/day	slope < -0.07/day
<b>Plateau</b>	Steady level with minimal trend up or down	-0.88/day < slope < 0.42/day	-0.07/day < slope < 0.07/day
<b>Slow Growth</b>	Sustained growth not rapid enough to be considered a Surge	0.42/day < slope < 2.45/day	0.07/day < slope < 0.21/day
<b>In Surge</b>	Currently experiencing sustained rapid and significant growth	2.45/day < slope	0.21/day < slope



# District Case Trajectories – last 10 weeks

Status	Number of Districts	
	Current Week	Last Week
Declining	17	(25)
Plateau	8	(5)
Slow Growth	8	(5)
In Surge	2	(0)

Curve shows smoothed case rate (per 100K)  
 Trajectories of states in label & chart box  
 Case Rate curve colored by Reproductive number






# District Hospital Trajectories – last 10 weeks


Status	Number of Districts	
	Current Week	Last Week
Declining	33	(28)
Plateau	2	(6)
Slow Growth	0	(1)
In Surge	0	(0)

Hospitalization by county is delayed, these data are current as of


**October 18<sup>th</sup>**



Curve shows smoothed hospitalization rate (per 100K) by district  
Hosp rate curve colored by Re number





# CDC's COVID-19 Community Levels



**Red outline indicates county had 200 or more cases per 100k in last week**



**Pale color indicates either beds or occupancy set the level for this county**

**Dark color indicates both beds and occupancy set the level for this county**



**Last week**

28-Oct-22




COVID-19 Community Levels - Use the Highest Level that Applies to Your Community				
New COVID-19 Cases Per 100,000 people in the past 7 days	Indicators	Low	Medium	High
Fewer than 200	New COVID-19 admissions per 100,000 population (7-day total)	<10.0	10.0-19.9	≥20.0
	Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average)	<10.0%	10.0-14.9%	≥15.0%
200 or more	New COVID-19 admissions per 100,000 population (7-day total)	NA	<10.0	≥10.0
	Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average)	NA	<10.0%	≥10.0%



The COVID-19 community level is determined by the higher of the new admissions and inpatient beds metrics, based on the current level of new cases per 100,000 population in the past 7 days




# District Trajectories with Community Levels



Curve shows smoothed case rate (per 100K)  
 CDC's new [Community Level](#) aggregated to district level in label & chart box color  
 Case Rate curve colored by Trajectory



**District's Aggregate Community Level**  
 Aggregate level a simple mean of all levels for counties in district  
**Case rate Trajectory**



# Estimating Daily Reproductive Number – Redistributed gap



October 24<sup>th</sup> Estimates

Region	Date Confirmed $R_e$	Date Confirmed Diff Last Week
State-wide	0.890	-0.033
Central	0.989	0.059
Eastern	0.958	-0.028
Far SW	0.502	-0.021
Near SW	0.741	-0.329
Northern	0.955	-0.062
Northwest	0.901	-0.016


## Methodology

- Wallinga-Teunis method (EpiEstim<sup>1</sup>) for cases by confirmation date
- Serial interval: updated to discrete distribution from observations (mean=4.3, Flaxman et al, Nature 2020)
- Using Confirmation date since due to increasingly unstable estimates from onset date due to backfill

1. Anne Cori, Neil M. Ferguson, Christophe Fraser, Simon Cauchemez. A New Framework and Software to Estimate Time-Varying Reproduction Numbers During Epidemics. American Journal of Epidemiology, Volume 178, Issue 9, 1 November 2013, Pages 1505–1512, <https://doi.org/10.1093/aje/kwt133>



Skipping Weekend Reports & holidays biases estimates  
Redistributed “big” report day to fill in gaps, and then estimate R from “smoothed” time series




# Wastewater Monitoring


## Wastewater provides a coarse early warning of COVID-19 levels in communities

- Overall in the US, there is an increase in sites with increased levels of virus compared to 15 days ago
- Current virus levels are at or exceeding max of previous historical levels, has slowed, though more sites are entering upper quintiles


US Historic percentile of current detected levels over the past weeks



Virginia - Historic percentile of current detected levels over the past weeks





Percent Change over 15 days for the past weeks (US) - Proportions



# COVID-like Illness Activity

## COVID-like Illness (CLI) gives a measure of COVID transmission in the community

- Emergency Dept (ED)-based CLI is more correlated with case reporting
- Urgent Care (UC) is a leading indicator but prone to some false positives
- **Current trends in UC CLI have plateaued since May 2022, mixed by region**






# Hospitalizations and Severe Outcomes

Data Source: [CDC Data Tracker](#)


## Proportion of most severe outcomes decreasing among those who are hospitalized

- ICU has declined from ~20% of hospitalized to nearly 10% since initial Omicron wave
- Also seen across all age-groups
- Similar levels of decline seen in VA
- Regionally more variation


Number of hospitalized COVID-19 patients




Intensive care unit (ICU) admission among hospitalized COVID-19 patients (%)



Invasive mechanical ventilation (IMV) among hospitalized COVID-19 patients



Mortality among hospitalized COVID-19 patients (%)




## Virginia wide – full pandemic

VA statewide ICU & Ventilation proportions (14 day rolling average)




## Virginia wide – recent

VA statewide ICU & Ventilation proportions (14 day rolling average)




## Virginia Regional ICU percent

VA Regional ICU proportions (14 day rolling average)



## Virginia Regional Ventilation %

VA Regional Ventilation proportions (14 day rolling average)




# Hospitalizations in VA by Age

## Age distribution in hospitals relatively stable


- Recent change in pediatric hospitalizations, though not higher yet than in previous months

Note: These data are lagged and based on hospital reporting HHS

## Virginia Hospitalizations by Age (all ages)



## Pediatric Hospitalizations by Age (0-17yo)



Data Source: [Delphi](#) and [HHS](#)

# SARS-CoV2 Variants of Concern

Emerging new variants will alter the future trajectories of pandemic and have implications for future control

- **Emerging variants can:** Increase transmissibility, increase severity (more hospitalizations and/or deaths), and limit immunity provided by prior infection and vaccinations

## Omicron Updates

- Soup of variants has grown to 41% of variants from 36% last week
- BQ.1.1 continues to show quick growth up to 10.5% from 7%, with BQ.1.\* accounting for another 7%
- BF.7 continues steady slow growth at 7.3%
- BA.4.6 remains steady at 11-13% for last 4 weeks
- BQ.1.1 recently seeing growth in England and other countries that mimics past variants of concern that have gone on to dominate
- BA.2.75.2 also shows signs as being a potential candidate as a future variant of concern, has recently [been shown to have significant immune escape](#)

## Relative Growth Advantages



[COV-spectrum](#)


covSPECTRUM

Enabled by data from **GISAID**

Known variants

Which variant would you like to explore?


Editor's choice ▼



[COV-spectrum](#)

“Editor’s choice”

Variants to watch






# Pandemic Pubs

Both BQ.1.1 and XBB show substantial immune escape and significant negation of many pharmaceutical interventions. XBB is significantly more immune evasive than BA.2.75.2 and BQ.1.1 against plasma from all breakthrough infections, comparable to or even exceeding the level of escape displayed by SARS-CoV-1 against SARS-CoV-2 convalescent plasma.

a

Pango lineages	REGN 10933	REGN 10987	REGN+10987	COV2-2196	COV2-2130	COV2-2196+2130	BRIL-196	BRIL-198	BRIL-196+198	S309	DXP-604	LY-CoV-1404	SA58	SA55	SA55+SA58	Additional RBD mutations
BA.2	*	590	821	4312	6.3	8.2	8530	8990	8610	852	219	0.9	5.1	7.2	7.8	
BA.2.3.20	121	*	199	15	*	26	14	*	24	897	181	9.7	20	4.6	7.8	K444R+N450D+L452M+N460K+R493Q
BA.2.10.4	*	*	*	*	289	501	2109	7990	3984	706	6348	1.3	4.3	4.9	5.0	G446S+F486P+R493Q+S494P
BJ.1	*	*	*	3076	*	5985	7609	*	*	709	166	*	8163	3.7	8.6	D339H+R346T+L368I+V445P+G446S+V483A+F490V
XBB	*	*	*	*	*	*	*	*	*	963	*	*	8805	5.3	9.8	D339H+R346T+L368I+V445P+G446S+N460K+F486S+F490S+R493Q
BA.2.75	278	*	410	119	352	121	1730	6622	3861	672	5920	2.2	246	4.3	9.6	
BL.1	260	*	511	93	*	174	1251	*	3075	508	7193	2.8	7975	6.3	10	R346T
BR.1	319	*	679	117	*	170	1992	*	3160	564	6689	*	1616	5.9	9.7	L452R+K444M
BN.2.1	390	*	701	59	303	109	4101	*	8444	6979	8901	1.7	4960	5.7	9.4	K356T+F490S
BN.1	344	*	599	70	*	166	3683	*	7791	*	6012	3.3	8295	4.9	9.0	R346T+K356T+F490S
BA.2.75.2	*	*	*	*	*	*	*	*	*	852	*	3.0	6922	5.9	9.7	R346T+F486S
BM.1.1	*	*	*	*	*	*	*	*	*	879	*	2.3	8823	5.2	8.9	R346T+F486S
BM.1.1.1	*	*	*	*	*	*	*	*	*	956	*	1.9	8082	4.8	10.5	R346T+F486S+F490S
BR.2	*	*	*	*	*	*	*	*	*	921	*	2.6	7263	4.7	10.5	R346T+L452R+F486I
CA.1	*	*	*	*	*	*	*	*	*	897	*	3.2	6927	6.0	11.5	R346T+L452R+F486S
BA.4/5	*	520	709	*	23	40	7124	*	*	1055	6264	0.8	3.9	5.0	4.5	
BA.4.6.1	*	2338	5402	*	*	*	4763	*	7809	4456	4634	1.2	50	4.8	9.9	R346T
BA.5.6.2	*	*	*	*	*	*	4636	*	7883	1408	5892	1662	58	5.1	8.9	K444T
BQ.1	*	*	*	*	*	*	*	*	*	1709	*	1905	44	6.6	9.2	K444T+N460K
BU.1	*	*	*	*	*	*	*	*	*	1082	*	26	56	5.3	10.5	K444M+N460K
BQ.1.1	*	*	*	*	*	*	*	*	*	5581	*	900	5.9	10.3	R346T+K444T+N460K	
Pseudovirus IC50 (ng/mL)													<100	100~1,000	>1,000	



Researchers in Beijing characterize multiple concerning immune escape variants using plasma from breakthrough infections in those vaccinated with three doses of CoronaVac. **Similar to BQ.1.1, XBB also escapes Evusheld and Bebtelovimab.** BU.1, BR.2, BM.1.1.1, CA.1, and XBB all displayed moderate hACE2 binding relative to previously widely circulating variants of BA.2 and BA.5.

<https://www.biorxiv.org/content/10.1101/2022.09.15.507787v3>







[https://twitter.com/yunlong\\_cao/status/1577343549120872448](https://twitter.com/yunlong_cao/status/1577343549120872448)

<https://github.com/aswarren/ncov-clades-schema>



# Pandemic Pubs

Both BQ.1.1 and XBB show substantial immune escape and significant negation of many pharmaceutical interventions. XBB is significantly more immune evasive than BA.2.75.2 and BQ.1.1 against plasma from all breakthrough infections. BQ.1.1 shows strong growth in NY and has been detected at increasing levels throughout the country.



<https://twitter.com/MoritzGerstung/status/1582266906777526274>

<https://twitter.com/JPWeiland/status/1581735046704074752>

<https://cov->

[spectrum.org/explore/United%20States/AllSamples/Past6M/variants?nextcladePangolLineage=BQ.1.1\\*&](https://cov-spectrum.org/explore/United%20States/AllSamples/Past6M/variants?nextcladePangolLineage=BQ.1.1*&)

# Pandemic Pubs

XBB, a SARSCoV2 recombinant, shows strong growth in Singapore. Reportedly 17% of recent infections are reinfections. Increase in hospitalized cases remains proportional to the increase in local cases, likely as a result of strong vaccine uptake in the country.



Over the last 28 days,

Infected  
**143,627**

**99.8%**  
Had No or Mild Symptoms

**0.2%**  
Required Oxygen Supplementation

**0.03%**  
ICU

**0.02%**  
Died



As of 18 Oct 2022, 12:00pm

### New Cases

**8,243**  
7-day Moving Average of Local Cases

**716**  
Local PCR

**10,837**  
Local ART

**15**  
Imported PCR

**366**  
Imported ART

**8,097**  
Discharged

**5**  
Died

**1.31**  
Week on Week Infection Ratio



As of 17 Oct 2022 (COVID-19 vaccines under National Vaccination Programme only)

  
**92% of total population**  
Received at least one dose

  
**95% of eligible population**  
**92% of total population**  
Completed full regimen

  
**79% of total population**  
Received booster shots



### COVID-19

## COVID-19 Situation at a Glance →

As of 18 Oct 2022, 12:00pm

**Hospitalised**  
**661**  
**58**  
Required Oxygen Supplementation


**14**  
ICU

<https://twitter.com/sailorrooscout/status/1582388135434268673>  
[https://cov-spectrum.org/explore/Singapore/AllSamples/Past6M/variants?nextcladePangoLineage=XBB\\*&https://www.moh.gov.sg/news-highlights/details/opening-remarks-by-minister-for-health-mr-ong-yek-kung-at-the-moh-press-conference-to-update-on-the-covid-19-situation-on-15-october-2022](https://cov-spectrum.org/explore/Singapore/AllSamples/Past6M/variants?nextcladePangoLineage=XBB*&https://www.moh.gov.sg/news-highlights/details/opening-remarks-by-minister-for-health-mr-ong-yek-kung-at-the-moh-press-conference-to-update-on-the-covid-19-situation-on-15-october-2022)



As of 18 October 2022, 12pm


## Local Cases in the Last 28 Days by Severity of Condition



Asymptomatic/Mild Symptoms	143,289 (99.8%)
Ever Required Oxygen Supplementation in General Ward	263 (0.2%)
Ever in ICU	42 (0.03%)
Deceased	33 (0.02%)

Proportion of all samples from 2022-10-04 to 2022-10-10


Proportion Absolute




XBB  
**63.7%**  
Proportion ⓘ  
**48.7-76.4%**  
Confidence int. ⓘ



# United States Case & Hospitalizations




Status	Number of States	
	Current Week	Last Week
<b>Declining</b>	46	(48)
<b>Plateau</b>	6	(5)
<b>Slow Growth</b>	2	(1)
<b>In Surge</b>	0	(0)




Status	Number of States	
	Current Week	Last Week
<b>Declining</b>	16	(22)
<b>Plateau</b>	28	(21)
<b>Slow Growth</b>	8	(9)
<b>In Surge</b>	1	(1)

# Virginia and Her Neighbors

## Cases



## Hospitalizations




# Around the World – Various trajectories

## Confirmed cases

### Daily new confirmed COVID-19 cases per million people


7-day rolling average. Due to limited testing, the number of confirmed cases is lower than the true number of infections.



## Hospitalizations

### Weekly new hospital admissions for COVID-19 per million people

Weekly admissions refer to the cumulative number of new admissions over the previous week.



# Statistical Ensemble Models - Hospitalizations

Ensemble methodology that combines the Adaptive with machine learning and statistical models such as:


- Autoregressive (AR, ARIMA)
- Neural networks (LSTM)
- Kalman filtering (EnKF)
- Phase-based ensembling (phase)

Weekly forecasts of hospitalizations done at state level.

Models chosen because of their track record in disease forecasting and to increase diversity and robustness.

Ensemble forecast provides additional 'surveillance' for making scenario-based projections.

Also submitted to CDC Forecast Hub.




# Current Influenza Hospitalization Forecast

## Statistical models for submitting to CDC FluSight forecasting challenge


- Similar to COVID-19 case forecasts, uses a variety of statistical and ML approaches to forecast weekly hospital admissions for the next 4 weeks for all states in the US

### Hospital Admissions for Influenza and Forecast for next 4 weeks (UVA ensemble)



Initial forecasts have wide uncertainty due to noisiness in data due to low numbers of hospitalizations

### Hospital Admissions for Influenza and Forecast for next 4 weeks (CDC FluSight Ensemble)






# Previous projections comparison - Cases

- Previous projections continue to track observed cases
- Projection from 2 weeks ago projected continued decline but cases plateaued
- Projection from 4 weeks ago projected slower decline better capturing recent plateau


## Projection from 1 week ago

Virginia Daily Confirmed - Comparison 2022-10-14




## Projection from 3 weeks ago

Virginia Daily Confirmed - Comparison 2022-09-30



## Projection from 3 months ago

Virginia Daily Confirmed - Comparison 2022-07-02






# Previous projections comparison - Hospitalizations

- Previous projections have tracked observed hospitalizations reasonably well, though the case to hospitalization ratios may be shifting as model is under predicting


## Projection from 1 week ago

Virginia Daily Hospitalized - Comparison 2022-10-14




## Projection from 3 weeks ago

Virginia Daily Hospitalized - Comparison 2022-09-30



## Projection from 3 months ago

Virginia Daily Hospitalized - Comparison 2022-07-02




# Scenario Modeling Hub – COVID-19 (Round 15)

Collaboration of multiple academic teams to provide national and state-by-state level projections for 4 aligned scenarios

- Round 15 results published
  - Scenarios: Test benefits of reformulated fall boosters w/ and w/out a new variant
  - Timing of reformulated boosters is one of the axes

<https://covid19scenariomodelinghub.org/viz.html>

Projected Incident Cases by Epidemiological Week and by Scenario for Round 15 - US  
( - Projection Epiweek; -- Current Week)




# Scenario Modeling Hub – Influenza (Round 1)

Collaboration of multiple academic teams to provide national and state-by-state level projections for 4 aligned scenarios

- Round 1 results recently published
  - Impact of missed flu seasons on pre-season immunity
  - Testing different seasonal vaccine coverage and efficacy
  - Projected from Aug 14<sup>th</sup> 2022
- High degree of uncertainty as previous 2 seasons have been irregular and there is still limited data for this season available
- Demonstrates importance of good vaccine coverage especially if previous immunity is weak

<https://fluscenariomodelinghub.org/viz.html>

Projected Incident Hospitalizations by Epidemiological Week and by Scenario for Round 1 - US  
( - Projection Epiweek; -- Current Week)



# Key Takeaways

Projecting future cases precisely is impossible and unnecessary.

Even without perfect projections, we can confidently draw conclusions:

- **Case rates have continued to decline though hospitalizations have shown some recent growth**
- VA weekly case rate is slightly down at 81 per 100K from 84 per 100K
  - US weekly case rate is flat remaining at 74 per 100K from 74 per 100K
  - VA hospital occupancy (rolling 7 day mean of 455 slightly down from 482 a week ago) down but experiencing recent activity
- Sub-variant prevalence has started to grow rapidly, BA.5 subvariants seem to be accelerating
- Projections from last week remain largely on target with limited impact of Fall Winter scenario, however hospitalization trajectories

The situation continues to change. Models continue to be updated regularly.

# Additional Analyses

---

# References

Venkatramanan, S., et al. "Optimizing spatial allocation of seasonal influenza vaccine under temporal constraints." *PLoS Computational Biology* 15.9 (2019): e1007111.

Arindam Fadikar, Dave Higdon, Jiangzhuo Chen, Bryan Lewis, Srinivasan Venkatramanan, and Madhav Marathe. Calibrating a stochastic, agent-based model using quantile-based emulation. *SIAM/ASA Journal on Uncertainty Quantification*, 6(4):1685–1706, 2018.

Adiga, Aniruddha, Srinivasan Venkatramanan, Akhil Peddireddy, et al. "Evaluating the impact of international airline suspensions on COVID-19 direct importation risk." *medRxiv* (2020)

NSSAC. PatchSim: Code for simulating the metapopulation SEIR model. <https://github.com/NSSAC/PatchSim>

Virginia Department of Health. COVID-19 in Virginia. <http://www.vdh.virginia.gov/coronavirus/>

Biocomplexity Institute. COVID-19 Surveillance Dashboard. <https://nssac.bii.virginia.edu/covid-19/dashboard/>

Google. COVID-19 community mobility reports. <https://www.google.com/covid19/mobility/>

Biocomplexity page for data and other resources related to COVID-19: <https://covid19.biocomplexity.virginia.edu/>



# Questions?

## Points of Contact

Bryan Lewis  
[brylew@virginia.edu](mailto:brylew@virginia.edu)

Srini Venkatramanan  
[srini@virginia.edu](mailto:srini@virginia.edu)

Madhav Marathe  
[marathe@virginia.edu](mailto:marathe@virginia.edu)

Chris Barrett  
[ChrisBarrett@virginia.edu](mailto:ChrisBarrett@virginia.edu)

## Biocomplexity COVID-19 Response Team

Aniruddha Adiga, Abhijin Adiga, Hannah Baek, Chris Barrett, Golda Barrow, Richard Beckman, Parantapa Bhattacharya, Jiangzhuo Chen, Clark Cucinell, Patrick Corbett, Allan Dickerman, Stephen Eubank, Stefan Hoops, Ben Hurt, Ron Kenyon, Brian Klahn, Bryan Lewis, Dustin Machi, Chunhong Mao, Achla Marathe, Madhav Marathe, Henning Mortveit, Mark Orr, Joseph Outten, Akhil Peddireddy, Przemyslaw Porebski, Erin Raymond, Jose Bayoan Santiago Calderon, James Schlitt, Samarth Swarup, Alex Telionis, Srinivasan Venkatramanan, Anil Vullikanti, James Walke, Andrew Warren, Amanda Wilson, Dawen Xie